Seventy-six people with relapsed or refractory B-cell lymphoma treated at the N.N. Alexandrov National Cancer Centre with an academic, non-commercial CAR T-cell product had a 57.5% complete response rate, and 67% were alive at four years.
Published as "Academic anti CD19 CAR-T cell therapy for relapsed/refractory B-cell lymphomas in real-world clinical practice: a prospective cohort study". From June 2021 to December 2025 the trial (NCT07524816) enrolled 76 patients aged 23 to 68 at the N.N. Alexandrov National Cancer Centre of Belarus, treated with an anti-CD19 CAR T-cell product made with a lentiviral vector. The authors' rationale is that commercial products cost too much for routine use.
Belarus offers CAR T-cell therapy through an academic product rather than a commercial one; the authors describe it as the only option where commercial products are not accessible.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/